Trichoscopy and LC-OCT findings in sonidegib-induced alopecia in patients with advanced basal cell carcinoma

Sonidegib is a Hedgehog pathway inhibitor (HHIs) used as first-line systemic treatment for patients with advanced basal cell carcinoma (aBCC). Alopecia is reported as a frequent adverse event (AE), occurring in 49% of patients. Forty-five patients with aBCC were treated with sonidegib between Decemb...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Dermatology reports Ročník 17; číslo 1
Hlavní autoři: Ciobotariu, Irina, Palmisano, Gerardo, Caldarola, Giacomo, Piccerillo, Alfredo, Tassone, Francesco, Cappilli, Simone, Di Stefani, Alessandro, Peris, Ketty
Médium: Journal Article
Jazyk:angličtina
Vydáno: Italy PAGEPress Publications, Pavia, Italy 06.02.2025
PAGEPress Publications
Témata:
adverse events
Alopecia
basal cell carcinoma
Case Report
hedgehog inhibitors
line-field confocal optical coherence tomography
ISSN:2036-7392, 2036-7406
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Sonidegib is a Hedgehog pathway inhibitor (HHIs) used as first-line systemic treatment for patients with advanced basal cell carcinoma (aBCC). Alopecia is reported as a frequent adverse event (AE), occurring in 49% of patients. Forty-five patients with aBCC were treated with sonidegib between December 2022 and December 2023; among them, 11/45 patients developed alopecia. Trichoscopic features included yellow dots, black dots, exclamation mark hairs, and broken hairs. Upon LC-OCT examination, yellow dots were seen as dilated follicular dark spaces containing malted nonhomogeneous material and outlined by bright collarets; black dots corresponded to normal-sized follicular ostia filled with bright, homogeneous material and cadaverized hair; exclamation mark hairs were short dark dysmorphic hairs with a different size of proximal and distal end and broken hairs were short dysmorphic hairs. LC-OCT may provide additional insights of early signs and clinical evolution of sonidegib-induced alopecia in patients with aBCC.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Publisher's note: all claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Ethics approval and consent to participate: this study was carried out in accordance with the Declaration of Helsinki. Ethics committee approval was waived because the study affected neither routine diagnostic nor therapeutic management. This retrospective review of patient data did not require ethical approval in accordance with local/national guidelines. The patients in this manuscript have given written informed consent to the publication of their case details, including images. All data were de-identified before use.
Consent for publication: the patients gave their written consent to use their personal data for the publication of this case report and any accompanying images.
Kp has received consulting fees and honoraria unrelated to this work from Abbvie, Almirall, Biogen, Celgene, Janssen Galderma, Lilly, Novartis, Pierre Fabre, Sandoz, Sanofi and Sun Pharma. All other authors have no conflicts of interest to declare.
ISSN:2036-7392
2036-7406
DOI:10.4081/dr.2024.10113